Watson To Pay Elan $18M To Settle Naprelan IP Suit

Law360, New York (March 9, 2009, 12:00 AM EDT) -- Watson Pharmaceuticals Inc. will pay $18 million to Elan Corp. PLC to settle patent litigation over Watson's generic version of Naprelan, or naproxen sodium tablets, Watson announced Friday.

The company will not market or sell its product until Elan's patent on the drug expires in 2014 or is found invalid or unenforceable, according to a Watson statement.

Friday's settlement resolves three patent infringement suits and an antitrust case between Watson and Elan, according to James Monroe, a partner at Finnegan Henderson Farabow Garrett & Dunner LLP,...
To view the full article, register now.